LYNN HEALTH SCIENCE INSTITUTE IS LOOKING FOR PARTICIPANTS
PAID CLINICAL TRIAL
- Lasting 2 years
- 39 Clinic Visits
YOU MAY BE ELIGIBLE TO PARTICIPATE IF YOU MEET THE FOLLOWING CRITERIA:
Male or Female 60-85 yrs old
Overall Healthy Patient
Learn More About the LocationOklahoma City, OK
You may be eligible to take part in the study because you have early Alzheimer’s disease (AD). Alzheimer’s is a type of disease in which abnormal proteins, called amyloid and tau, accumulate in the brain and damage nerve cells. People with Alzheimer’s often have trouble thinking, speaking, remembering things, and performing their daily activities. This condition is common in older people and gets worse over time.
Only people between 60 and 85 years of age who are diagnosed with early AD can take part in the study. All participants must have a study partner who is available to accompany them to study site visits and provide information about the participant to the study doctor. The study partner can be a family member, or someone who knows them very well on a weekly basis, such as a friend or person helping with their routine care.
The purpose of the study is to look at whether aducanumab (ADUHELM™, also known as BIIB037, the study drug) can help slow the development of AD symptoms in people with early AD.
Lynn Institute is a leader in introducing new medications to the market through our clinical trials program. Visit our Participation Information page for Frequently Asked Questions, to see current clinical trials listed, and to find out where each trial is being conducted.
Find out More About Our Participation ProgramParticipation Information